Articles On Suda Pharmaceuticals (ASX:SUD)

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in...

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

SUDA Pharmaceuticals (SUD) has its lead product for short-term insomnia, ZolpiMist, approved by the Chile Ministry of Health SUDA’s partner, Teva Pharmaceuticals, submitted the application to the Chilean authority in May 2021 and was grant...

Last week California Governor Gavin Newsom signed Assembly Bill (AB-45), formally permitting the sales of hemp-derived CBD products in the state. Hemp has been legalised at the US federal level since 2018, but state agencies have been slow...

Retail giant Amazon has rejigged its cannabis policy, allowing employees who were previously fired for testing positive for marijuana to reapply for jobs. The company has now excluded marijuana from its comprehensive pre-employment drug scr...

The Boston Beer Company (NYSE:SAM) is set to launch a new range of non-alcoholic cannabis-infused drinks in Canada with the help of Australian listed Althea Group Holdings’ (ASX:AGH) subsidiary. Peak processing Solutions will research and d...

03 Sep 2021 - Suda Pharmaceuticals (ASX: SUD) has appointed Dr John Maher to its scientific advisory board for the iNKT cell therapy platform.

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Virginia is the latest US state to legalise marijuana and they’re celebrating with the first annual CannaFest VA cannabis trade show on September 19. The event will feature a concert, and a custom car and motorcycle exhibition but no, you c...

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Massachusetts based cannabis operator MariMed has just announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio’s® to create a line-up of cannabis-infused vegan and dairy ice cream. The ice cream will cont...

The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The new appointee’s responsibilities include technology transfer, manufacturing, and quality aspects for the production of the cell therapy for clinical development stages.

The biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that Angel Medical Systems had completed its first commercial implantation in the US of the Guardian device – a cardiac detection monitor and pat...

The Community College of Denver (CCD) has just launched a cannabis business program in Colorado. The new program offers students the opportunity to earn an Associate of Applied Science degree designed to prepare them to become business mana...

The biotechnology company released its fourth-quarter report, unveiling cash receipts for the quarter of $68,000 and net outflow of $909,000 from operating activities for the quarter.

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

After starting the day in negative territory, the Australian bourse recovered to finish higher. The ASX 200 closed 0.17 per cent up, at 7,348 points while the ASX Emerging Companies Index closed 0.71 per cent up at 2,203. Most sectors were...

This week Technicorum Holdings announced an upcoming token sale and launch of The CanCoin – a cannabis token designed to solve market friction and monetisation in the European cannabis market and to help build blockchain-based solutions for...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM...

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

Connecticut has become the latest US state to legalise recreational use of marijuana. The state’s governor has just signed a bill to allow people aged 21 and older to possess and consume marijuana, making it the 19th US state to do so. Here...

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Plenty of action on the biotech front today has provided ASX investors with some mouth-watering gains. Suda Pharma (ASX:SUD) led the pack, popping by as much as 44 per cent after announcing an oversubscribed $3.65 million capital raise. The...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

SUDA Pharmaceuticals (ASX:SUD) has announced it has signed a global, exclusive agreement with Imperial College London for a novel invariant Natural Killer T cell therapy platform.

It was an ugly day on Australia’s bourse following the plunge on Wall Street on Friday. The ASX 200 lost 1.81 per cent, closing at 7,235 points while the ASX Emerging Companies Index shed 2.56 per cent, closing at 2,093. The selling was spa...

The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

There was plenty of action in the US regulatory front within the cannabis sector this week. A couple of major legislations during the week could potentially shake up the US cannabis industry. The Marijuana Opportunity Reinvestment and Expun...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

In 2021, which of Europe and North America is the place to be for ASX cannabis stocks?   The case for Europe A few years ago there would’ve been no question that it was North America with Canada legalising recreational cannabis as well as h...

A cannabis-based drug has been listed on Australia’s Pharmaceutical Benefits Scheme for the first time, as medical marijuana gains increased acceptance. The move means that an estimated 116 Aussies with a rare form of epilepsy known as Drav...

April 20 has come and gone, but ASX cannabis companies aren’t getting that high — they’re actually low. Of the 36 pot companies in the space, 27 have lost ground over the last fortnight. Just seven have advanced. Gains were led by Wide Open...

The number of medical cannabis prescriptions issued under Australia’s special access scheme just keeps on growing. There were a record 9,959 SAS Category B marijuana prescriptions issued in March, two and a half times the number from a year...

Australia’s medical marijuana industry is showing strong growth, according to an industry-leading biannual report. The Freshleaf Analytics report, released this morning, says that patient numbers have grown 15-fold over the past two and a h...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks. Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational ca...

Summary SUDA Pharmaceuticals Limited (ASX:SUD) is anticipated to make significant progress in its product pipeline in 2021. The healthcare company plans to secure new technologies that fit within its current areas of focus. SUDA also...

Summary SUDA Pharmaceuticals Limited (ASX:SUD) has raised A$2.7 million via successful completion of Placement Offer. The capital raising has provided SUDA with a strong cash balance to proceed with its drug development activities over...

Summary SUDA Pharmaceuticals (ASX:SUD) has obtained firm commitments for a A$2.76 million capital raising. Funds raised from the placement will support the Company in product developments for twelve months and aid in evaluating new ass...

SUDA Pharmaceuticals (ASX:SUD), a company focussed on oromucosal drug delivery, has announced it has received "firm commitments" for a placement to raised over $2.7 million.

Summary SUDA Pharmaceuticals Limited (ASX:SUD) has recently released its Annual General Meeting presentation on the ASX. The presentation provides an insight into SUDA’s key achievements in 2020 and its focus for the upcoming year. Im...

Summary SUDA Pharmaceuticals (ASX:SUD) is a leading oro-mucosal drug delivery leader based in Australia. The Company’s management is presently working with the technical team to further bolster the intellectual property portfolio as it...